Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
FDA Approval for Daklinza
NS5A inhibitor for chronic hepatitis C infection
Indications: Daclatasvir (Daklinza) is a hepatitis C virus (HCV) NS5A inhibitor indicated for use with sofosbuvir for the treatment of chronic HCV genotype 3 infection.
Dosing: The recommended starting dosage is 60 mg taken orally once daily with or without food in combination with sofosbuvir. Recommended treatment duration is 12 weeks. Reduce dosage to 30 mg once daily with strong CYP3A inhibitors and increase dosage to 90 mg once daily with moderate CYP3A inducers.
Pharmacokinetics: The pharmacokinetic properties of daclatasvir were evaluated in healthy adult subjects and in subjects with chronic HCV. Administration of daclatasvir tablets in HCV-infected subjects resulted in approximately dose-proportional increases in Cmax, AUC, and Cmin up to 60 mg once daily. Steady state is anticipated after approximately 4 days of once-daily daclatasvir administration. Exposure of daclatasvir was similar between healthy and HCV-infected subjects.
Efficacy: In phase-III ALLY-3 clinical trial involving a total of 152 treatment-naïve and treatment-experienced subjects with chronic HCV genotype 3 infection and compensated liver disease, results showed that 98% of the treatment-naïve participants with no cirrhosis of the liver and 58% of the treatment-naïve participants with cirrhosis achieved sustained virolgic response (SVR) while 92% of treatment-experienced patients with no cirrhosis of the liver and 69% with cirrhosis achieved SVR.
Side Effects/Risks: Serious symptomatic bradycardia may occur in patients taking amiodarone with sofosbuvir in combination with another HCV direct-acting agent, including Daklinza. The most common adverse reactions with sofosbuvir are headache and fatigue.
Source: Highlights of Prescribing Information: Daklinza (daclatasvir). FDA website. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206843Orig1s000lbl.pdf. Revised July 2015. Accessed August 3, 2015.
This Week's Must Reads
Must Reads in Infectious Diseases
Rapid Point of Care Test for Influenza, J Am Board Fam Med; 2019 Mar; Dale, et al
Invasive GBS Infections in Nonpregnant US Adults, JAMA Intern Med; ePub 2019 Feb 18; Francois Watkins, et al
Prescribed Opioids & Risk of CAP in Patients with HIV, JAMA Intern Med; 2019 Jan 7; Edelman, et al
Influenza Vaccination Safety During Hospitalization, Mayo Clin Proc; ePub 2019 Jan 8; Tartof, et al
Hospitalization Trends for Drug-Use Associated IE, Ann Intern Med; ePub 2018 Dec 4; Schranz, et al